MedReleaf and Tikun Olam partnership pools MMJ research data
- seniorsmmjnetwork
- Feb 11, 2015
- 2 min read
Curious as to what made the former Vice President of Business Development for the world-renowned Mount Sinai Hospital in Toronto, Canada, decide to enter the Medical Marijuana business? It was a trip to Israel and a visit with some seniors.
In the United States, research into the medical benefits of Marijuana have been hampered by Federal regulations, namely, Marijuana being a Schedule 1 drug. Fortunately things are progressing towards a reclassification due to support from the Medical community. We do however, have the benefit of research carried out in other countries. Medical professionals in Israel have been studying Medical Marijuana for decades and now they have teamed up with a Canadian company, MedReleaf, to produce over 20 new studies.
“When I left Mount Sinai, I knew that I wanted to be part of a successful business, but I also knew that it would have to be a business in which we were helping people with the quality of their lives; to help improve the world, bit by bit,” says Neil Closner.
Skeptical at first by the offer, Neil set out to discover the real world impact this could make. He boarded a jet to meet with Tikun Olam, Israel's largest government approved producer of Medical Marijuana. After a brief meeting in Tel Aviv, they ventured to a Seniors facility and that is when the decision was made.
Closner spoke to many of the residents, some of which made remarkable improvements under a supervised regimen of MMJ. “After my time in that Israeli nursing home, I got back on the plane, saying to myself, ‘Wow, this business is legitimate. Let’s get back to Canada, fill out the forms for Health Canada, and let’s start improving lives,” says Closner.
The new partnership between MedReleaf and Tikun Olam, (Hebrew for “repairing the world”) is exciting in that it provides significant insights into years of professionally conducted studies. They now have combined access to data from over 7,000 patients to dissect the effectiveness and efficacy of various strains of Medical Marijuana. Going forward it can provide health care providers with recommended treatments / strains for a variety of ailments.
This is a wonderful step forward and we anxiously await some of the results. The focus is on the two main cannabinoids, THC and CBD. THC is well known for treating sleep disorders, managing pain, nausea, inflammation, and indigestion. CBD is a non-psychoactive (doesn't make you "high") cannabinoid found in Marijuana that has been shown to have a positive impact on disorders such as Multiple Sclerosis, Arthritis, Cancer and Epilepsy, amongst other ailments.
We recommend you read the entire story here --
Press release -
Q&A with MedReleaf CEO, Neil Closner
Comments